Highlights from the upcoming #ASCO24: We are excited to unveil the topline results of sunvozertinib's global pivotal phase II WU-KONG1 Part B study in NSCLC with EGFR exon20ins mutations. https://lnkd.in/eBpUfN3a #exon20ins #nsclc #oncology
About us
Dizal Pharmaceutical Co., Ltd (Ticker: 688192 ) is a commercial stage biopharmaceutical company. At Dizal we aspire to discover and develop differentiated therapeutics for the treatment of cancer and immunological diseases. Building on our extensive expertise in translational science and molecular design, we have established an internationally competitive portfolio of five clinical-stage assets with two leading assets in global pivotal studies and one already approved.
- Website
-
http://www.dizalpharma.com/
External link for Dizal Pharmaceutical
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Shanghai, Shanghai
- Type
- Public Company
- Founded
- 2017
- Specialties
- oncology and immunology
Locations
-
Primary
Get directions
No 199 Liang Road
Shanghai, Shanghai 201203, CN
-
Get directions
Chaoyang District
Beijing, Beijing 100020, CN
Employees at Dizal Pharmaceutical
Updates
-
We are delighted to announce that sunvozertinib has received breakthrough therapy designation from the US FDA for the first-line treatment of EGFR exon20ins NSCLC, and the results of its global pivotal study in relapsed and refractory setting WU-KONG1 PARTB will be reported as an oral presentation at #ASCO24. https://lnkd.in/g7AC-5jJ #exon20ins #nsclc #oncology
FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of EGFR exon20ins NSCLC
dizalpharma.com
-
A phase 2 pivotal study (WU-KONG6) of our potential BIC assest sunvozertinib for platinum-pretreated NSCLC patients with EGFR exon20ins were published in the The Lancet Respiratory Medicine (IF: 76.2). https://lnkd.in/gcKT87dG #exon20ins #nsclc #oncology #lancet
Dizal’s Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine
dizalpharma.com
-
We are thrilled to showcase the remarkable research findings of golidocitinib and DZD8586 presented at #ASH23, highlighting Dizal's advances in hematological oncology with full commitment to developing life-changing medicines globally. https://lnkd.in/gqx2EqEQ #ptcl #lymphoma #hematology #ash23
Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH
dizalpharma.com
-
We are gratified to share golidocitinib's global pivotal trial results presented orally at #ASH23 and simultaneously published in the #Lancet Oncology, offering new hope for patients with r/r PTCL facing a poor prognosis. https://lnkd.in/g_3WR8Wb #ptcl #lymphoma #hematology
Dizal’s Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL
dizalpharma.com
-
Exciting news from Dizal! We're proud to share that we'll be showcasing our strength in hematological oncology with robust data at #ASH23. https://lnkd.in/gzNtfBfc #ptcl #lymphoma #hematology
Dizal Highlights Its Advances in Hematological Portfolio at 2023 ASH, Featuring Breakthroughs in Lymphoma Treatment
dizalpharma.com
-
We are thrilled to announce at #ESMO23: Sunvozertinib showcases its best-in-class potential as a first-line treatment for NSCLC patients with EGFR Exon20ins. https://lnkd.in/gj2jhhjA #exon20ins #nsclc #oncology
Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon20ins Mutation-Positive Non-Small Cell Lung Cancer
dizalpharma.com
-
We are going to present latest data of sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20ins mutations at #ESMO23. #exon20ins #nsclc #oncology
-
-
We are pleased to announce that the China National Medical Products Administration (NMPA) has granted priority review to golidocitinib, Dizal’s “First-in-Class” JAK1-only inhibitor, for the treatment of relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). https://lnkd.in/gYAUrDTA #ptcl #lymphoma #hematology
Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL
dizalpharma.com
-
We are thrilled to announce that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). https://lnkd.in/gUgCzyxJ #ptcl #lymphoma #hematology
Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL
dizalpharma.com